New Results
Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer
Julia K. Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard B. Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B. Corcoran, Iwei Yeh, Boris C. Bastian, Petr Starostik, Kimberly Newsom, Victor R Olivas, Alexander M. Wolff, James S. Fraser, Eric A. Collisson, Caroline E. McCoach, D. Ross Camidge, Jose Pacheco, Lyudmila Bazhenova, Tianhong Li, Trever G. Bivona, Collin M. Blakely
doi: https://doi.org/10.1101/374181
Julia K. Rotow
1Department of Medicine, University of California, San Francisco
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
Philippe Gui
1Department of Medicine, University of California, San Francisco
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
Wei Wu
1Department of Medicine, University of California, San Francisco
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
Victoria M. Raymond
3Guardant Health, Inc
Richard B. Lanman
3Guardant Health, Inc
Frederic J. Kaye
4Department of Medicine, University of Florida
Nir Peled
5Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel
Ferran Fece de la Cruz
6Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School
Brandon Nadres
6Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School
Ryan B. Corcoran
6Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School
Iwei Yeh
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
7Departments of Dermatology and Pathology, and Clinical Cancer Genomics Laboratory, University of California, San Francisco
Boris C. Bastian
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
7Departments of Dermatology and Pathology, and Clinical Cancer Genomics Laboratory, University of California, San Francisco
Petr Starostik
8Department of Pathology Immunology and Laboratory Medicine, University of Florida
Kimberly Newsom
8Department of Pathology Immunology and Laboratory Medicine, University of Florida
Victor R Olivas
1Department of Medicine, University of California, San Francisco
Alexander M. Wolff
9Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
James S. Fraser
9Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Eric A. Collisson
1Department of Medicine, University of California, San Francisco
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
Caroline E. McCoach
1Department of Medicine, University of California, San Francisco
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
D. Ross Camidge
10University of Colorado
Jose Pacheco
10University of Colorado
Lyudmila Bazhenova
11University of California, San Diego
Tianhong Li
12Departiment of Internal Medicine, University of California, Davis
Trever G. Bivona
1Department of Medicine, University of California, San Francisco
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
Collin M. Blakely
1Department of Medicine, University of California, San Francisco
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
Posted May 24, 2019.
Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer
Julia K. Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard B. Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B. Corcoran, Iwei Yeh, Boris C. Bastian, Petr Starostik, Kimberly Newsom, Victor R Olivas, Alexander M. Wolff, James S. Fraser, Eric A. Collisson, Caroline E. McCoach, D. Ross Camidge, Jose Pacheco, Lyudmila Bazhenova, Tianhong Li, Trever G. Bivona, Collin M. Blakely
bioRxiv 374181; doi: https://doi.org/10.1101/374181
Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer
Julia K. Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard B. Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B. Corcoran, Iwei Yeh, Boris C. Bastian, Petr Starostik, Kimberly Newsom, Victor R Olivas, Alexander M. Wolff, James S. Fraser, Eric A. Collisson, Caroline E. McCoach, D. Ross Camidge, Jose Pacheco, Lyudmila Bazhenova, Tianhong Li, Trever G. Bivona, Collin M. Blakely
bioRxiv 374181; doi: https://doi.org/10.1101/374181
Subject Area
Subject Areas
- Biochemistry (11703)
- Bioengineering (8718)
- Bioinformatics (29127)
- Biophysics (14930)
- Cancer Biology (12048)
- Cell Biology (17353)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14143)
- Epidemiology (2067)
- Evolutionary Biology (18266)
- Genetics (12219)
- Genomics (16765)
- Immunology (11841)
- Microbiology (28003)
- Molecular Biology (11551)
- Neuroscience (60804)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3229)
- Physiology (4939)
- Plant Biology (10383)
- Synthetic Biology (2877)
- Systems Biology (7333)
- Zoology (1642)